ZACKS INVESTMENT MANAGEMENT

Position in HALO — Halozyme Therapeutics, Inc.

CIK 1086483 Chicago, IL

Position in HALO

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$1,993,963

+$215,157 QoQ

Shares Held

30,852

+16.7% QoQ

Ownership

0.026%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2020

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

ZACKS INVESTMENT MANAGEMENT holds $41,029,792 across 10 Biotechnology names. HALO ranks #5 (4.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	55,082	$24,596,316
2	KRYS	Krystal Biotech, Inc.	17,919	$4,628,835
3	MIRM	Mirum Pharmaceuticals, Inc.	36,889	$3,407,804
4	ALNY	Alnylam Pharmaceuticals, Inc.	7,857	$2,599,644
5	HALO	Halozyme Therapeutics, Inc. This page	30,852	$1,993,963
6	ADMA	Adma Biologics, Inc.	118,702	$1,069,505
7	TARS	Tarsus Pharmaceuticals, Inc.	14,879	$1,043,761
8	ARVN	Arvinas, Inc.	66,978	$709,966

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,993,963	30,852	+16.7%	Shares	Sole	2026-05-14
2025-12-31	$1,778,806	26,431	+1.2%	Shares	Sole	2026-02-17
2025-09-30	$1,915,713	26,121	-29.5%	Shares	Sole	2025-11-14
2021-12-31	$1,488,855	37,027	+6.4%	Shares	Sole	2022-02-15
2021-09-30	$1,415,867	34,805	+10.5%	Shares	Sole	2021-11-15
2021-06-30	$1,430,551	31,503	+0.5%	Shares	Sole	2021-08-16
2021-03-31	$1,306,939	31,349	+1.7%	Shares	Sole	2021-05-17
2020-12-31	$1,316,364	30,821	+15.4%	Shares	Sole	2021-02-16
2020-09-30	$701,859	26,707	-1.0%	Shares	Sole	2020-11-16
2020-06-30	$723,172	26,974	—	Shares	Sole	2020-08-14
No filing history on record for this holder in this stock.